Obtained in a collaborative project with the US-based Paragon Bioservices, the data showed that CAP cells were able to produce very high titers of RSV.
When compared to other production systems, RSV produced in CAP cells showed high-level of functional G-protein resulting in a very effective RSV vaccine with positive impact on attenuated-vaccine studies.
CEVEC Pharmaceuticals COO and CFO Dr Rainer Lichtenberger noted again CAP cells prove their enormous potential and significant advantages over many currently used production systems for vaccines.
"Next to Cytomegalovirus, Influenza and others, this is another striking example that CAP cells can efficiently propagate disease relevant human viruses. We were very pleased to work with Paragon on this project and benefited from their experience in vaccine production. This collaboration was extremely pleasant and successful," Dr Lichtenberger added.
CAP cells, an immortalized cell line, are derived from primary human amniocytes that meet the highest ethical and regulatory standards. These cells grow in serum-free suspension culture and allow for stable production of proteins and viruses / vaccines.
The cells have the potential to serve as a fully documented production cell line for a highly effective RSV vaccine.
Image: Transmission electron micrograph of respiratory syncytial virus. Photo: Courtesy of Kauczuk